New Neoadjuvant Combination for HER+ Breast CancerNew Neoadjuvant Combination for HER+ Breast Cancer

A presurgery combination of trastuzumab emtansine and pertuzumab was significantly better than the standard of care, paclitaxel and trastuzumab, for HER2+ invasive breast cancer. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news